Common use of Goal of Research Collaboration Clause in Contracts

Goal of Research Collaboration. (a) The goal of the Research Collaboration is, through the combined efforts of ISIS and ZENECA scientists and using ISIS and ZENECA technology, to discover Compounds having the potential to be commercialized as drugs for human therapeutic use. The Research Collaboration will be conducted by ISIS and ZENECA and will be managed by the Joint Research Committee. (b) Research relating to a Target includes the elaboration of necessary cellular, biochemical and molecular-biological approaches (i.e., the development of the knowledge not already available to the two parties, the development and setting up of relevant assays) towards the inhibition of the expression of the protein target molecules by Antisense Technology as well as the conception, design, synthesis and development of therapeutic entities, including the characterization of their biophysical and pharmacokinetic properties. Subject to Section 3.1 the research relating to a Target will explore all reasonable therapeutic applications of a Compound. (c) The Research Collaboration will include access to all ISIS Technology for purposes of developing Compounds within the terms of article 7 except as described below. The Research Collaboration does not include research relating to or access by ZENECA to ISIS technology or Know-How relating to [ * ] of oligonucleotides. When and if the Parties decide to include such technology and research in the Research Collaboration, they will negotiate in good faith additional technology access fees to reflect ISIS investment in the technology and an appropriate increase in the Research Payments to fund additional research relating thereto. (d) ZENECA and ISIS will work together exclusively on the use of Antisense Technology to discover, develop or commercialize antisense inhibitors for any Target for which ZENECA has an Active Target Program. ISIS will not license or assign to a Third Party any ISIS Target Patents relating to a particular target for so long as ZENECA has an Active Target Program for that Target.

Goal of Research Collaboration. (a) The goal of the Research Collaboration is, through the combined efforts of ISIS and ZENECA scientists and using ISIS and ZENECA technology, to discover Compounds having the potential to be commercialized as drugs for * CONFIDENTIAL TREATMENT REQUESTED 2 human therapeutic use. The Research Collaboration will be conducted by ISIS and ZENECA and will be managed by the Joint Research Committee. (b) Research relating to a Target includes the elaboration of necessary cellular, biochemical and molecular-biological approaches (i.e., the development of the knowledge not already available to the two parties, the development and setting up of relevant assays) towards the inhibition of the expression of the protein target molecules by Antisense Technology as well as the conception, design, synthesis and development of therapeutic entities, including the characterization of their biophysical and pharmacokinetic properties. Subject to Section 3.1 the research relating to a Target will explore all reasonable therapeutic applications of a Compound. (c) The Research Collaboration will include access to all ISIS Technology for purposes of developing Compounds within the terms of article 7 except as described below. The Research Collaboration does not include research relating to or access by ZENECA to ISIS technology or Know-How relating to [ * ] of oligonucleotides]. When and if the Parties decide to include such technology and research in the Research Collaboration, they will negotiate in good faith additional technology access fees to reflect ISIS investment in the technology and an appropriate increase in the Research Payments to fund additional research relating thereto. (d) ZENECA and ISIS will work together exclusively on the use of Antisense Technology to discover, develop or commercialize antisense inhibitors for any Target for which ZENECA has an Active Target Program. ISIS will not license or assign to a Third Party any ISIS Target Patents relating to a particular target for so long as ZENECA has an Active Target Program for that Target.

Goal of Research Collaboration. (a) The goal of the Research Collaboration is, through the combined efforts of ISIS and ZENECA scientists and using ISIS and ZENECA technology, to discover Compounds having the potential to be commercialized as drugs for * CONFIDENTIAL TREATMENT REQUESTED human therapeutic use. The Research Collaboration will be conducted by ISIS and ZENECA and will be managed by the Joint Research Committee. (b) Research relating to a Target includes the elaboration of necessary cellular, biochemical and molecular-biological approaches (i.e., the development of the knowledge not already available to the two parties, the development and setting up of relevant assays) towards the inhibition of the expression of the protein target molecules by Antisense Technology as well as the conception, design, synthesis and development of therapeutic entities, including the characterization of their biophysical and pharmacokinetic properties. Subject to Section 3.1 the research relating to a Target will explore all reasonable therapeutic applications of a Compound. (c) The Research Collaboration will include access to all ISIS Technology for purposes of developing Compounds within the terms of article 7 except as described below. The Research Collaboration does not include research relating to or access by ZENECA to ISIS technology or Know-How relating to [ * ] of oligonucleotides]. When and if the Parties decide to include such technology and research in the Research Collaboration, they will negotiate in good faith additional technology access fees to reflect ISIS investment in the technology and an appropriate increase in the Research Payments to fund additional research relating thereto. (d) ZENECA and ISIS will work together exclusively on the use of Antisense Technology to discover, develop or commercialize antisense inhibitors for any Target for which ZENECA has an Active Target Program. ISIS will not license or assign to a Third Party any ISIS Target Patents relating to a particular target for so long as ZENECA has an Active Target Program for that Target.